Paper Details

  1. Home
  2. Paper Details

Using the incremental net benefit framework for quantitative benefit-risk analysis in regulatory decision-making--a case study of alosetron in irritable bowel syndrome.

Author: ByrneMichael F, ColleyLindsey, HauberA Brett, JohnsonF Reed, LyndLarry D, NajafzadehMehdi, SculpherMark J, WillanAndrew R

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study evaluated the incremental net benefit (INB) framework for undertaking quantitative benefit-risk assessment by performing a quantitative benefit-risk analysis of alosetron for the treatment of irritable bowel syndrome from the patients' perspective.
Paper Details　
Original Abstract of the Article :
There is consensus that a more transparent, explicit, and rigorous approach to benefit-risk evaluation is required. The objective of this study is to evaluate the incremental net benefit (INB) framework for undertaking quantitative benefit-risk assessment by performing a quantitative benefit-risk an...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1524-4733.2009.00595.x

データ提供：米国国立医学図書館（NLM）

Quantitative Benefit-Risk Analysis: A Case Study of Alosetron for Irritable Bowel Syndrome

This study explores the use of the incremental net benefit (INB) framework for quantitative benefit-risk analysis of alosetron, a medication for irritable bowel syndrome (IBS). The researchers analyzed the benefit-risk profile of alosetron from the patients' perspective, aiming to provide a transparent and rigorous approach to decision-making.

INB Framework for Decision-Making

The study demonstrates the potential of the INB framework for conducting quantitative benefit-risk assessments in regulatory decision-making. It highlights the importance of considering both the benefits and risks associated with medications from the patient's perspective.

Making Informed Decisions

This research emphasizes the need for a more transparent and rigorous approach to benefit-risk evaluation in healthcare. By adopting frameworks like the INB, we can make more informed decisions regarding medication use, ensuring that patients receive optimal care.

Dr.Camel's Conclusion

Like a camel carefully navigating a treacherous desert path, we must approach medication decisions with a balanced perspective, weighing both the potential benefits and risks. This study demonstrates the value of frameworks like INB for making informed decisions in healthcare, ensuring that patients receive appropriate and safe treatment.

Date :
  1. Date Completed 2010-09-20
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

19744297

DOI: Digital Object Identifier

10.1111/j.1524-4733.2009.00595.x

Related Literature

Article Analysis
・Side Effects of alosetron
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.